What others are saying
- No events
An Israeli Publicly traded company that developed a novel non-invasive test to detect genetic changes in bronchial epithelial cells using sputum sample from subjects with pulmonary nodules to aid in the identification of subjects with Lung Cancer. Based on: Duet system and the combined analysis “Target FISH”, combination of morphology and FISH of PRE-SELECTED bronchial epithelial cells population.
The company is looking to collaborate with local Pathology labs and national distributors.
For more information regarding this unique business opportunity please contact us
IBD Consulting provides complete business development services for leading-edge companies wishing to enter new and emerging markets. From initial consultation and market appraisals, to establishing your solution in your target market, we can assist your company in achieving its international business development goals. At IBD Consulting we choose to work with companies using innovative technologies in the medical, agri and hi-tech sectors, with a focus on companies coming from and seeking entry into the Israeli, Australian and New Zealand markets.
Are you looking to expand your business in to the Australian market? lets partner up!